Which Breast Cancer Treatment Should You Choose? at www.ResourcesForBreastCancer.com
ResourcesForBreastCancer.com :: Screening For Breast Cancer With No Compression And No Radiation

Screening For Breast Cancer With No Compression And No Radiation


Who would have thought that a technology for detecting breast cancer used today actually had its' roots dating back to 480 B.C.? Digital Infrared Thermal Imaging (DITI) is a fairly new technology that represents a practice that was once used by Hippocrates. This technology is based on a technique that Hippocrates would use as he spread mud over his patients and then watched to see which areas dried first. It was in those places on the body that could show a disease. It wasn't until 1957 that the first modern application of thermography came into existence when a Canadian doctor discovered that the skin temperature over a breast tumor was higher than that of healthy tissue. By 1982, the Food and Drug Administration approved thermography and classified it as an additional diagnostic tool for the detection of breast cancer. However, DITI was introduced as a diagnostic tool before strict protocols were established for both the technicians who performed the scans and the doctors who interpreted the scans. Shortly after its initial beginnings, DITI fell out of favor as a diagnostic tool in the medical community. There are now stringent protocols both for testing and interpreting. Perhaps due to these guidelines, thermography (as with all digital technology) has exploded in its technique and capabilities. Thermal cameras detect heat given off by the body and display it as a picture on a computer monitor. These images are unique to the person and they remain stable over time. It is because of these characteristics that thermal imaging is a valuable and effective screening tool to determine changes that could point to trouble down the road. As we all know, early cancer detection is important to survival. Another advantage is that, unlike mammography, there is no radiation and no compression of the breast; two significant reasons some women refuse mammography. Thermography measures temperature changes in the body. Tumors create their own blood vessels. Where there are more blood vessels, there is more heat. It is in these areas on the body that the camera detects changes in heat or temperature. Medical doctors who interpret the breast scans are board certified thermologists. Thermography can be utilized by women of all ages. It is not limited by breast density and is ideal for women who have had cosmetic or reconstructive surgery. Cancer typically has a 15 year life span from onset to death. Ideally, women should begin thermographic screenings by age 25. A woman diagnosed with breast cancer at age 40 possibly had the cancer as early as age 30. Since most women do not have a mammogram until age 40, there is a critical time period from age 25 to 39 that thermography could be extremely beneficial. Thermography does not replace mammography. However, it is an additional tool that is available to women. By combining both technologies, the detection rate increases to 95-98%, surpassing either technology as a stand-alone therapy. Thermographic screening is not covered by most insurance companies but is surprisingly affordable for most people. For more information or to find a certified clinic in your area, go to www.proactivehealthonline.com.
About the Author

Brenda Witt is co-owner of Proactive Health Solutions in Southern California. She has worked in the medical field for 9 years and is now an American College of Clinical Thermology (ACCT) certified thermographer in the Orange County area. To contact Brenda, email her at brenda@proactivehealthonline.com.

Written by: Brenda Witt

Updates and Recent News

Chemotherapy Drug Can Cause Fatal Reaction
CHICAGO -- Cremophor-containing paclitaxel, a drug used in treating cancer, has been associated with allergic reactions, some fatal, U.S. researchers said. Researchers at Northwestern University Feinberg School of Medicine identified 287 unique cases of hypersensitivity reactions submitted to the FDA's Adverse Event Report System from 1997-2007, with 109 deaths in patients who received Cremophor-based paclitaxel, a solvent-administered taxane chemotherapy. Adverse event reports generally only represent from 1 percent to 10 percent of actual incidence, so the number of hypersensitivity reactions and deaths is likely significantly higher, the researchers said. Study leader Dr. Charles Bennett of Northwestern's Feinberg.
To Read More...

Older Breast Cancer Patients May Be Under-treated
Elderly breast cancer patients who received care in a community hospital setting may have been under-diagnosed, under-staged and under-treated, as per a report in the recent issue of Archives of Surgery, one of the JAMA/Archives journals. The number of older patients with breast cancer has increased along with overall elderly population, as per background information in the article. About half of patients with breast cancer are older than 65 years and 35 percent are older than 70; 77 percent of breast cancer deaths occur in women older than 55. Choosing the appropriate therapy for older patients is a challenge, because a number of have other serious illnesses in addition to their cancer that may threaten their health and shorten their lives. Questions remain about the best screening protocols for elderly women, as well. Some current guidelines suggest that women stop having mammograms at age 70, while others provide no upper limit....
To Read More...

Gene Signature Helps Predict Breast Cancer Prognosis
Vanderbilt-Ingram Cancer Center researchers have uncovered a gene signature that may help predict clinical outcomes in certain types of breast cancer. In the Journal of Clinical Investigation, Harold (Hal) Moses, M.D., and colleagues report that this gene signature which is associated with the transforming growth factor-beta (TGF- & #946;) signaling pathway correlates with reduced relapse-free survival in patients with breast cancer, especially in those with estrogen receptor (ER) positive tumors. The results suggest that assessing TGF- & #946; signaling may be a useful aid in determining breast cancer prognosis and in guiding treatment. The work also sheds light on how TGF- & #946; affects tumor growth and progression. TGF- & #9.
To Read More...